{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:50:38Z","timestamp":1764791438412,"version":"3.46.0"},"reference-count":19,"publisher":"Archives of Pathology and Laboratory Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,12,1]]},"abstract":"<jats:sec>\n                    <jats:title>Context.\u2014<\/jats:title>\n                    <jats:p>In the face of the coronavirus disease 2019 (COVID-19) pandemic response, it was worthwhile to test the safety and efficacy of COVID-19 convalescent plasma (CCP) transfusion.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective.\u2014<\/jats:title>\n                    <jats:p>To establish a CCP donation program based on the availability of recovered COVID-19 patients and the practical limitations in recruiting clinically valid donors in a multicultural setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design.\u2014<\/jats:title>\n                    <jats:p>From March to June 2020, we developed a program for collection of COVID-19 CCP as part of the treatment options for patients affected with COVID-19. From an initial population of 3746 candidates, only those with positive polymerase chain reaction results in at least 2 separate tests were considered. This filter reduced the eligible donor pool to 488 patients. After other exclusions were applied, such as language barrier, age, accessibility to donation, and comorbidities, the final count was 267 potentially eligible donors, which represented only 54.7% (267 of 488) of preselected candidates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.\u2014<\/jats:title>\n                    <jats:p>Eighty donors were called. Approximately a third of the calls provided additional challenges as outlined by the following 4 reasons: limited functional understanding of English; schedule availability due to rotating work timetables; transportation restrictions since public transport services were severely restricted during lockdown; and lost to follow-up. Finally, a total of 38 valid donors participated, upon whom 45 apheresis procedures were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.\u2014<\/jats:title>\n                    <jats:p>As a summary of our experience, we can conclude that despite the limitations we were able to establish an effective program. A total of 90 units of CCP were collected before the pandemic curve began to flatten toward the end of June 2020.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.5858\/arpa.2021-0198-sa","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T13:40:30Z","timestamp":1629294030000},"page":"1479-1484","source":"Crossref","is-referenced-by-count":0,"title":["Challenges in Establishing a Coronavirus Disease 2019 (COVID-19) Convalescent Plasma Donation Program in a Multicultural Environment"],"prefix":"10.5858","volume":"145","author":[{"given":"Manuel","family":"Algora","sequence":"first","affiliation":[{"name":"From Pathology and Laboratory Institute (Algora), Khalifa University, Abu Dhabi, United Arab Emirates"},{"name":"National Reference Laboratory, Abu Dhabi, United Arab Emirates (Algora, Tagamtam, Acena, Totaan, Grabski, AbdelWareth)"},{"name":"Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, Ohio (Algora)"},{"name":"College of Medicine & Health Sciences, Department of Pathology, Khalifa University, Abu Dhabi, United Arab Emirates (Algora, AbdelWareth)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tori","family":"Mehmood","sequence":"additional","affiliation":[{"name":"Clinical Data Abstractor Department (Mehmood, Madison), Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debrina L.","family":"Madison","sequence":"additional","affiliation":[{"name":"Clinical Data Abstractor Department (Mehmood, Madison), Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jawahir","family":"AlAmeri","sequence":"additional","affiliation":[{"name":"Medical Subspecialties Institute (AlAmeri), Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed","family":"Abuzakouk","sequence":"additional","affiliation":[{"name":"Allergy and Immunology Institute (Abuzakouk), Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mylka","family":"Tagamtam","sequence":"additional","affiliation":[{"name":"National Reference Laboratory, Abu Dhabi, United Arab Emirates (Algora, Tagamtam, Acena, Totaan, Grabski, AbdelWareth)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorlin","family":"Acena","sequence":"additional","affiliation":[{"name":"National Reference Laboratory, Abu Dhabi, United Arab Emirates (Algora, Tagamtam, Acena, Totaan, Grabski, AbdelWareth)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Totaan","sequence":"additional","affiliation":[{"name":"National Reference Laboratory, Abu Dhabi, United Arab Emirates (Algora, Tagamtam, Acena, Totaan, Grabski, AbdelWareth)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gloria","family":"Grabski","sequence":"additional","affiliation":[{"name":"National Reference Laboratory, Abu Dhabi, United Arab Emirates (Algora, Tagamtam, Acena, Totaan, Grabski, AbdelWareth)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naima","family":"Oumeziane","sequence":"additional","affiliation":[{"name":"SEHA-Abu Dhabi Blood Bank, Abu Dhabi, United Arab Emirates (Oumeziane, Rajani)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pritesh","family":"Rajani","sequence":"additional","affiliation":[{"name":"SEHA-Abu Dhabi Blood Bank, Abu Dhabi, United Arab Emirates (Oumeziane, Rajani)"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lynzi","family":"Taylor","sequence":"additional","affiliation":[{"name":"Data Resources Management (Taylor), Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Guzman","sequence":"additional","affiliation":[{"name":"Executive Administration Office (Guzman), Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laila Osama","family":"AbdelWareth","sequence":"additional","affiliation":[{"name":"Pathology and Laboratory Institute (AbdelWareth), Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates"},{"name":"National Reference Laboratory, Abu Dhabi, United Arab Emirates (Algora, Tagamtam, Acena, Totaan, Grabski, AbdelWareth)"},{"name":"College of Medicine & Health Sciences, Department of Pathology, Khalifa University, Abu Dhabi, United Arab Emirates (Algora, AbdelWareth)"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3906","published-online":{"date-parts":[[2021,8,18]]},"reference":[{"key":"2021112418364452300_i1543-2165-145-12-1479-b01","doi-asserted-by":"crossref","unstructured":"Luke\n              TC,\n            \n            \n              Kilbane\n              EM,\n            \n            \n              Jackson\n              JL,\n            \n            \n              Hoffman\n              SL.\n            \n          \n          Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?\n          \n            Ann Intern Med\n          .\n\t\t\t\t\t2006;\n\t\t\t\t\t145(8):\n\t\t\t\t\t599\u2013\n\t\t\t\t\t609.","DOI":"10.7326\/0003-4819-145-8-200610170-00139"},{"key":"2021112418364452300_i1543-2165-145-12-1479-b02","doi-asserted-by":"crossref","unstructured":"McGuire\n              LW,\n            \n            \n              Redden\n              WR.\n            \n          \n          The use of convalescent human serum in influenza pneumonia\u2014a preliminary report.\n\t\t\t\t\tAm J Public Health (N Y).\n\t\t\t\t\t1918;\n\t\t\t\t\t8(10):\n\t\t\t\t\t741\u2013\n\t\t\t\t\t744.","DOI":"10.2105\/AJPH.8.10.741"},{"key":"2021112418364452300_i1543-2165-145-12-1479-b03","doi-asserted-by":"crossref","unstructured":"Maiztegui\n              J,\n            \n            \n              Fernandez\n              NJ,\n            \n            \n              De Damilano\n              AJ.\n            \n          \n          Efficacy of immune plasma in treatment of Argentine haemorrhagic fever and association between treatment and a late neurological syndrome.\n\t\t\t\t\tLancet.\n\t\t\t\t\t1979;\n\t\t\t\t\t2(8154):\n\t\t\t\t\t1216\u2013\n\t\t\t\t\t1217.","DOI":"10.1016\/S0140-6736(79)92335-3"},{"key":"2021112418364452300_i1543-2165-145-12-1479-b04","doi-asserted-by":"crossref","unstructured":"Hung\n              IF,\n            \n            \n              To\n              KK,\n            \n            \n              Lee\n              CK,\n            \n            et al.\n          \n          Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.\n\t\t\t\t\tClin Infect Dis.\n\t\t\t\t\t2011;\n\t\t\t\t\t52(4):\n\t\t\t\t\t447\u2013\n\t\t\t\t\t456.","DOI":"10.1093\/cid\/ciq106"},{"key":"2021112418364452300_i1543-2165-145-12-1479-b05","unstructured":"World Health Organization.\n          Use of convalescent whole blood or plasma collected from patients recovered from Ebola virus disease for transfusion, as an empirical treatment during outbreaks.\n\t\t\t\t\tVersion 1.0. September 2014.https:\/\/apps.who.int\/iris\/rest\/bitstreams\/604045\/retrieve. Accessed February 20,2020."},{"key":"2021112418364452300_i1543-2165-145-12-1479-b06","doi-asserted-by":"crossref","unstructured":"Arabi\n              Y,\n            \n            \n              Balkhy\n              H,\n            \n            \n              Hajeer\n              AH.\n            \n          \n          Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East Respiratory Syndrome coronavirus infection: a study protocol.\n\t\t\t\t\tSpringerplus.\n\t\t\t\t\t2015;\n\t\t\t\t\t4:\n\t\t\t\t\t709.","DOI":"10.1186\/s40064-015-1490-9"},{"key":"2021112418364452300_i1543-2165-145-12-1479-b07","unstructured":"World Health Organization.\n          Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. March 13, 2020.\n\t\t\t\t\thttps:\/\/www.who.int\/docs\/default-source\/coronaviruse\/clinical-management-of-novel-cov. Accessed February 20,2020."},{"key":"2021112418364452300_i1543-2165-145-12-1479-b08","unstructured":"US Food and Drug Administration.\n          Recommendations to reduce the possible risk of transmission of Creutzfeldt-Jakob disease and variant Creutzfeldt-Jakob disease by blood and blood components.\n\t\t\t\t\thttps:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/recommendations-reduce-possible-risk-transmission-creutzfeldt-jakob-disease-and-variant-creutzfeldt. Accessed October 15,2020."},{"key":"2021112418364452300_i1543-2165-145-12-1479-b09","unstructured":"American Association of Blood Banks.\n          Major changes in blood donor screenings. October 4, 2020.\n\t\t\t\t\thttps:\/\/www.aabb.org\/news-resources\/news\/article\/2020\/10\/04\/major-changes-in-blood-donor-screening. Accessed October 20,2020."},{"key":"2021112418364452300_i1543-2165-145-12-1479-b10","doi-asserted-by":"crossref","unstructured":"Abuzakouk\n              M,\n            \n            \n              Salah\n              K,\n            \n            \n              Algora\n              M,\n            \n            et al.\n          \n          Convalescent plasma efficacy in life-threatening COVID-19 patients admitted to the intensive care unit.\n\t\t\t\t\tJ Clin Med.\n\t\t\t\t\t2021;\n\t\t\t\t\t10(10):\n\t\t\t\t\t2113.","DOI":"10.3390\/jcm10102113"},{"key":"2021112418364452300_i1543-2165-145-12-1479-b11","doi-asserted-by":"crossref","unstructured":"Bonelli\n              F,\n            \n            \n              Sarasini\n              A,\n            \n            \n              Zierold\n              C,\n            \n            et al.\n          \n          Clinical and analytical performance of an automated serological test that identifies S1\/S2-neutralizing IgG in COVID-19 patients semiquantitatively.\n\t\t\t\t\tJ Clin Microbiol.\n\t\t\t\t\t2020;\n\t\t\t\t\t58(9):\n\t\t\t\t\t1224\u2013\n\t\t\t\t\t1220.","DOI":"10.1128\/JCM.01224-20"},{"key":"2021112418364452300_i1543-2165-145-12-1479-b12","unstructured":"United Arab Emirates population statistics\n          (2020).\n\t\t\t\t\thttps:\/\/www.globalmediainsight.com\/blog\/uae-population-statistics\/. AccessedOctober20,2020."},{"key":"2021112418364452300_i1543-2165-145-12-1479-b13","unstructured":"Erin\n              M.\n            \n          \n          Navigating the cultural minefield.\n\t\t\t\t\tHarv Bus Rev.\n\t\t\t\t\t2014;\n\t\t\t\t\t92:\n\t\t\t\t\t119\u2013\n\t\t\t\t\t124."},{"key":"2021112418364452300_i1543-2165-145-12-1479-b14","unstructured":"Comarow\n              A,\n            \n            \n              Harder\n              B.\n            \n          \n          2017-18 best hospitals honor roll and overview.\n\t\t\t\t\tUS News & World Report.\n\t\t\t\t\tAugust 8, 2017.https:\/\/health.usnews.com\/best-hospitals\/area\/oh\/cleveland-clinic-6410670?int=hp_hospitals_honor_roll_health. Accessed October 20,2020."},{"key":"2021112418364452300_i1543-2165-145-12-1479-b15","doi-asserted-by":"crossref","unstructured":"Riley\n              W,\n            \n            \n              Schwei\n              M,\n            \n            \n              McCullough\n              J.\n            \n          \n          The United States's potential blood donor pool: estimating the prevalence of donor- exclusion factors on the pool of potential donors.\n\t\t\t\t\tTransfusion.\n\t\t\t\t\t2007;\n\t\t\t\t\t47(7):\n\t\t\t\t\t1180\u2013\n\t\t\t\t\t1188.","DOI":"10.1111\/j.1537-2995.2007.01252.x"},{"key":"2021112418364452300_i1543-2165-145-12-1479-b16","doi-asserted-by":"crossref","unstructured":"To\n              L,\n            \n            \n              Dunnington\n              MS,\n            \n            \n              Thomas\n              C,\n            \n            \n              Love\n              K,\n            \n            \n              McCullough\n              J,\n            \n            \n              Riley\n              W.\n            \n          \n          The United States potential blood donor pool: estimating the prevalence of donor- exclusion factors on the pool of potential donors.\n\t\t\t\t\tTransfusion.\n\t\t\t\t\t2020;\n\t\t\t\t\t60(1):\n\t\t\t\t\t206\u2013\n\t\t\t\t\t215.","DOI":"10.1111\/trf.15573"},{"key":"2021112418364452300_i1543-2165-145-12-1479-b17","doi-asserted-by":"crossref","unstructured":"Ab\n              James,\n            \n            \n              Hillyer\n              CD,\n            \n            \n              Shaz\n              BH.\n            \n          \n          Demographic differences in estimated blood donor eligibility prevalence in the United States.\n\t\t\t\t\tTransfusion.\n\t\t\t\t\t2012;\n\t\t\t\t\t52(5):\n\t\t\t\t\t1050\u2013\n\t\t\t\t\t1061.","DOI":"10.1111\/j.1537-2995.2011.03416.x"},{"key":"2021112418364452300_i1543-2165-145-12-1479-b18","doi-asserted-by":"crossref","unstructured":"Wong\n              HK,\n            \n            \n              Lee\n              CK.\n            \n          \n          Pivotal role of convalescent plasma in managing emerging infectious diseases.\n\t\t\t\t\tVox Sang.\n\t\t\t\t\t2020;\n\t\t\t\t\t115(7):\n\t\t\t\t\t545\u2013\n\t\t\t\t\t547.","DOI":"10.1111\/vox.12927"},{"key":"2021112418364452300_i1543-2165-145-12-1479-b19","doi-asserted-by":"crossref","unstructured":"Wong\n              HK,\n            \n            \n              Lee\n              CK,\n            \n            \n              Hung\n              IF,\n            \n            et al.\n          \n          Practical limitations of convalescent plasma collection: a case scenario in pandemic preparation from influenza A (H1N1) infection.\n\t\t\t\t\tTransfusion.\n\t\t\t\t\t2010;\n\t\t\t\t\t50(9):\n\t\t\t\t\t1967\u2013\n\t\t\t\t\t1971.","DOI":"10.1111\/j.1537-2995.2010.02651.x"}],"container-title":["Archives of Pathology &amp; Laboratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/145\/12\/1479\/2965931\/i1543-2165-145-12-1479.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/meridian.allenpress.com\/aplm\/article-pdf\/145\/12\/1479\/2965931\/i1543-2165-145-12-1479.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,3]],"date-time":"2025-12-03T19:38:56Z","timestamp":1764790736000},"score":1,"resource":{"primary":{"URL":"https:\/\/aplm.kglmeridian.com\/view\/journals\/arpa\/145\/12\/article-p1479.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8,18]]},"references-count":19,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2021,8,18]]},"published-print":{"date-parts":[[2021,12,1]]}},"URL":"https:\/\/doi.org\/10.5858\/arpa.2021-0198-sa","relation":{},"ISSN":["1543-2165","0003-9985"],"issn-type":[{"type":"electronic","value":"1543-2165"},{"type":"print","value":"0003-9985"}],"subject":[],"published":{"date-parts":[[2021,8,18]]}}}